-
-
-
-
-
-
-
Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
-
-
-
-
-
-
-
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
-
-
-
-
-
-
-
Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Head
-
-
-
-
-
-
-
Biohaven's Rimegepant For Preventive Treatment Of Migraine Published In The Lancet
-
-
-
-
-
-
-
Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results And Recent Business Developments
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

